PRECISEU Matchmaking Platform

20 Oct – 13 Nov 2025 | Barcelona, Spain

Register
Register
Register

ADmit Therapeutics SL

SME

admit-therapeutics.com/en/Barcelona, Spain
2 profile visits

About

ADmit Therapeutics has developed the MAP-AD Test, the first prognostic blood test for Alzheimer's disease (AD) dementia. Using patented mitochondrial DNA biomarkers and AI, it predicts progression to AD in patients with first memory complaints, even before amyloid positivity. This facilitates early personalized interventions, optimizes clinical trial enrollment, and empowers patients and clinicians with crucial foresight. Our solution improves quality of life and offers significant economic savings.

Social media

Type of Cooperation

Clinical validation

Development Stage (TRL)

TRL 8

Sector

Diagnostics

Therapeutic Area

Diseases of the nervous system / neurology

Representatives

CEO

ADmit Therapeutics SL